

CITATION REPORT

List of articles citing

Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study

DOI: 10.1177/20458940211024955

Pulmonary Circulation, 2021, 11, 20458940211024955.

Source: <https://exaly.com/paper-pdf/80705096/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 ,	4.5	1
7	A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD. 1-18		
6	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
5	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
4	Successful treatment of pulmonary hypertension in a neonate with bronchopulmonary dysplasia: A case report and literature review. <i>10</i> , 11898-11907		0
3	Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis. 2023 , <i>36</i> , 44-50		0
2	Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience. <i>11</i> ,		0
1	Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future. 2023 , <i>16</i> , 503		0